Rajan Sharma
Stock Analyst at Goldman Sachs
(3.36)
# 2,437
Out of 4,698 analysts
205
Total ratings
52.9%
Success rate
4.4%
Average return
Main Sectors:
Stocks Rated by Rajan Sharma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: 0QW0 argenx SE | Reiterated: Buy | €973.00 | €905.60 | +7.44% | 19 | Aug 28, 2026 | |
| LON: AZN AstraZeneca PLC | Maintained: Buy | 16,070p → 16,300p | 12,006p | +35.77% | 42 | Aug 19, 2026 | |
| IMTX Immatics | Maintained: Buy | $12 → $12 | $9.38 | +25.80% | 5 | Aug 18, 2026 | |
| AUTL Autolus Therapeutics | Rated: Buy | $5.7 → $5.8 | $2.25 | +158.35% | 6 | Aug 11, 2026 | |
| GMAB Genmab | Maintained: Buy | $31 → $374 | $33.79 | +1,005.57% | 5 | Aug 7, 2026 | |
| IMCR Immunocore Holdings | Maintained: Buy | $73 → $74 | $36.70 | +101.63% | 13 | Aug 6, 2026 | |
| LON: 0NZT UCB SA | Maintained: Buy | €299.00 → €295.00 | €211.95 | +39.18% | 8 | Aug 3, 2026 | |
| LON: GSK GSK plc | Maintained: Hold | 1,890p | 1,847p | +2.36% | 31 | Jul 28, 2026 | |
| LON: 0MGB Genmab A/S | Maintained: Buy | kr 2,300 → kr 2,350 | kr 2,197 | +6.96% | 6 | Jul 21, 2026 | |
| VALN Valneva SE | Downgraded: Sell | $7.5 → $4.9 | $6.97 | -29.74% | 5 | Apr 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $7.25 → $5.81 | $13.45 | -56.80% | 3 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Sell | €1.30 → €1.01 | €2.31 | -56.20% | 5 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | €25.00 → €18.00 | €23.10 | -22.08% | 8 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $813 → $910 | $1,038.50 | -12.37% | 3 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.10 | - | 1 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.75 | - | 5 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $45 | $79.25 | n/a | 2 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €2.85 → €3.30 | €2.96 | n/a | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $110.08 | n/a | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $158 → $172 | $47.64 | n/a | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | CHF 2.00 | CHF 5.00 | n/a | 8 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $47 | $50.01 | n/a | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $129.58 | n/a | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $34.46 | n/a | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €90.00 → €100.00 | €164.70 | n/a | 6 | Feb 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €44.00 | €51.90 | n/a | 7 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $20 | $14.14 | n/a | 2 | May 4, 2022 |
argenx SE
Aug 28, 2026
Reiterated: Buy
Price Target: €973.00
Current: €905.60
Upside: +7.44%
AstraZeneca PLC
Aug 19, 2026
Maintained: Buy
Price Target: 16,070p → 16,300p
Current: 12,006p
Upside: +35.77%
Immatics
Aug 18, 2026
Maintained: Buy
Price Target: $12 → $12
Current: $9.38
Upside: +25.80%
Autolus Therapeutics
Aug 11, 2026
Rated: Buy
Price Target: $5.7 → $5.8
Current: $2.25
Upside: +158.35%
Genmab
Aug 7, 2026
Maintained: Buy
Price Target: $31 → $374
Current: $33.79
Upside: +1,005.57%
Immunocore Holdings
Aug 6, 2026
Maintained: Buy
Price Target: $73 → $74
Current: $36.70
Upside: +101.63%
UCB SA
Aug 3, 2026
Maintained: Buy
Price Target: €299.00 → €295.00
Current: €211.95
Upside: +39.18%
GSK plc
Jul 28, 2026
Maintained: Hold
Price Target: 1,890p
Current: 1,847p
Upside: +2.36%
Genmab A/S
Jul 21, 2026
Maintained: Buy
Price Target: kr 2,300 → kr 2,350
Current: kr 2,197
Upside: +6.96%
Valneva SE
Apr 22, 2026
Downgraded: Sell
Price Target: $7.5 → $4.9
Current: $6.97
Upside: -29.74%
Apr 9, 2026
Maintained: Sell
Price Target: $7.25 → $5.81
Current: $13.45
Upside: -56.80%
Apr 9, 2026
Rated: Sell
Price Target: €1.30 → €1.01
Current: €2.31
Upside: -56.20%
Apr 9, 2026
Rated: Hold
Price Target: €25.00 → €18.00
Current: €23.10
Upside: -22.08%
Feb 26, 2026
Maintained: Buy
Price Target: $813 → $910
Current: $1,038.50
Upside: -12.37%
Feb 17, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.10
Upside: -
Jan 9, 2026
Rated: Hold
Price Target: n/a
Current: $1.75
Upside: -
Jul 30, 2025
Maintained: Buy
Price Target: $35 → $45
Current: $79.25
Upside: n/a
Mar 21, 2025
Maintained: Hold
Price Target: €2.85 → €3.30
Current: €2.96
Upside: n/a
Oct 3, 2024
Maintained: Hold
Price Target: n/a
Current: $110.08
Upside: n/a
Aug 16, 2024
Maintained: Buy
Price Target: $158 → $172
Current: $47.64
Upside: n/a
Jul 30, 2024
Maintained: Hold
Price Target: CHF 2.00
Current: CHF 5.00
Upside: n/a
May 30, 2024
Initiated Coverage: Hold
Price Target: $47
Current: $50.01
Upside: n/a
May 30, 2024
Initiated Coverage: Buy
Price Target: n/a
Current: $129.58
Upside: n/a
Dec 20, 2023
Maintained: Buy
Price Target: n/a
Current: $34.46
Upside: n/a
Feb 13, 2023
Maintained: Hold
Price Target: €90.00 → €100.00
Current: €164.70
Upside: n/a
May 16, 2022
Maintained: Hold
Price Target: €44.00
Current: €51.90
Upside: n/a
May 4, 2022
Downgraded: Hold
Price Target: $40 → $20
Current: $14.14
Upside: n/a